Navigation Links
WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008
Date:10/23/2008

Earnings Conference Call to be Held on November 13, 2008 at 8:00 am

(Eastern) / 5:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong)

SHANGHAI, China, Oct. 23 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release unaudited financial results for the third quarter 2008 after the US market close on Wednesday, November 12, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The earnings release will be available on the investor relations section of its website at http://www.wuxiapptec.com .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 9:00 pm (Beijing/Hong Kong) on Thursday, November 13, 2008 to discuss its 2008 third quarter financial results and recent business activities. The conference call may be accessed by calling:

Conference ID: 70474888

United States 866-586-2813

China, Northern Region 10-800-611-0127

China, Southern Region 10-800-361-0079

Hong Kong 800-965-808

United Kingdom 0-800-056-9662

International +61-2-8524-6650

A telephone replay will be available two hours after the call's completion until December 14, 2008 at (US) +1-866-214-5335/ (HK) 800-901-596 / (China) 10-800-140-0386 / (UK) 0-800-731-7846 / (International) +61-2-8235-5000. Passcode: 70474888.

A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

For further information, please contact:

WuXi PharmaTech (Cayman) Inc.

Dr. Hai Mi

Executive Director of Investor Relations and Business Planning

Tel: +86-21-5046-3726

Email: ir@wuxiapptec.com

Burns McClellan

Juliane Snowden

Vice President of Investor Relations

Tel: +1-212-213-0006

Email: jsnowden@burnsmc.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance
2. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
3. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
4. WuXi PharmaTech (NYSE:WX) Maintains Original Strategy to Provide Toxicology Services in China
5. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
6. Warburg Pincus Acquires 5.4% of WuXi PharmaTechs Outstanding Ordinary Shares from United Overseas Bank
7. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
8. WuXi PharmaTech (NYSE: WX) Appoints Dr. Debra Yu as VP of Strategy
9. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
10. WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR
11. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Bioethics International, a not-for-profit organization focused ... developed, marketed and made accessible to patients around the world, ... had named the publication of the Good Pharma Scorecard ... is also featured as one of BMJ Open ,s ... year that are most frequently read. Ed Sucksmith ...
(Date:2/11/2016)... 11, 2016 --> ... "Company") (OTCQB: PSID), a life sciences company focused ... Thermomedics subsidiary, which markets the Caregiver® FDA-cleared non-contact ... in January 2016, including entering into agreements with ... sales growth, and establishing several near-term pipeline opportunities. ...
(Date:2/10/2016)... MONTREAL , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. ... is pleased to announce that Mitsui & Co. Ltd., ... bio-based succinic acid plant, is investing an additional CDN$25 ... equity, increasing its stake from 30% to 40%.  Mitsui ... of bio-succinic acid produced in Sarnia ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... that it has joined the Human Vaccines Project, a public-private partnership to ... cancer. , The Human Vaccines Project brings together leading pharmaceutical and ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/20/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce the attainment of record-setting ... result of the company,s laser focus on (and growing ... it,s comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... MedNet growth achievements in 2015 include: , ...
(Date:1/13/2016)... January 13, 2016 ... addition of the  "India Biometrics Authentication ... Forecast (2015-2020)"  report to their ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ...
Breaking Biology News(10 mins):